StockNews.AI
ABSI
StockNews.AI
127 days

Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

1. Absci will report Q1 2025 results on May 13, 2025. 2. Management will hold a conference call to discuss updates. 3. Absci's platform integrates AI and synthetic biology for drug creation. 4. Pipeline includes ABS-101 for inflammatory bowel disease treatment. 5. ABS-201 aims to revolutionize hair regrowth therapies.

Earnings
+0.97%Current Return
VS
-0.28%S&P 500
$3.0904/14 04:07 PM EDTEvent Start
$3.1204/15 10:38 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings report often correlates with price spikes. Positive expectations from a strong drug pipeline could boost investor confidence.

How important is it?

The article highlights a significant earnings release and innovative drug developments, likely to attract investor interest.

Why Short Term?

Immediate results and updates can influence stock price in the near term. Past earnings reports traditionally affect sentiment quickly.

Related Companies

ABTGILDREGNAMGNMRNA
April 14, 2025 16:05 ET  | Source: Absci Corporation VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event. About Absci Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube. Investor ContactAlex KhanVP, Finance & Investor Relationsinvestors@absci.com Media Contactpress@absci.com

Related News